Major cardiovascular adverse events in Fabry disease patients receiving agalsidase alfa
Medicina (B.Aires); 81 (2), 2021
Abstract Cardiovascular mortality (CVM) has become the major contributor to overall Fabry disease (FD) mortality in the enzyme replacement therapy (ERT) era. Our objectives were to describe causes and potential predictors of mortality in FD adult patients in Argentina, and to assess risk of major adverse...